@article{168650e7ada0436184710587d32cf1e2,
title = "A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial",
abstract = "Genes encoding vascular endothelial growth factor (VEGF) can potentially augment myocardial perfusion in patients with coronary artery disease (CAD). We conducted a randomised, double-blind, placebo-controlled gene therapy study with the adenovirus carrying VEGF121 (BIOBYPASS [AdGVVEGF121.10NH]).",
keywords = "Adenoviridae, Aged, Coronary Artery Disease, Double-Blind Method, Exercise Tolerance, Female, Gene Therapy, Gene Transfer Techniques, Genetic Vectors, Humans, Injections, Male, Middle Aged, Myocardium, Tomography, Emission-Computed, Single-Photon, Vascular Endothelial Growth Factor A, Ventricular Function, Left",
author = "Jens Kastrup and Erik J{\o}rgensen and Shmuel Fuchs and Sigrid Nikol and B{\o}tker, {Hans Erik} and Mariann Gy{\"o}ngy{\"o}si and Dietmar Glogar and Ran Kornowski",
year = "2011",
doi = "10.4244/EIJV6I7A140",
language = "English",
volume = "6",
pages = "813--8",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "Europa Group",
number = "7",
}